He or she is betting the stock will hold above $4 through that May expiration. They're also willing to buy shares if they are below that level and they are assigned. (See our Education Section .) ASTX rose 1.41 percent to $4.32 in late morning …
Aug. 1, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) today announced financial results for ... compared with a similar amount for the same prior year period. Stock-based compensation expense, a non-cash …
At the effective time of the merger on October 11, 2013 New York time, non-tendered shares of Astex (other than shares of common stock held in the treasury of Astex or by Otsuka Pharmaceutical, Autumn Acquisition Corporation or any …
(Reuters) - Otsuka Holdings Co’s (4578.T) $886 million bid for Astex Pharmaceuticals Inc ASTX.O has run into opposition from an ... indicating that investors expected a higher bid. The stock price gradually fell back to around $8.50 but shot …
with roughly $128 million in cash, cash equivalents and current and non-current marketable securities. ASTX has gained more than 18% in the past 1 month. The stock closed Monday's trading at $2.01, up 3.61%.
Today, Astex Therapeutics Limited became a wholly owned subsidiary of SuperGen, Inc. SuperGen purchased all outstanding shares of Astex for approximately $ 25 million in cash and 32.4 million shares of SuperGen common stock …
The combined company, which is expected to be listed on NASDAQ under the symbol ASTX, expects to have ... plus shares in SuperGen common stock representing 35 percent of the total post closing shares outstanding. Subsequently, …
The Bullish Continuation Wedge in Astex Pharmaceuticals (ASTX) tells us after a temporary interruption, the prior uptrend is set to continue. A Continuation Wedge (Bullish) represents a temporary interruption to an uptrend, taking the shape …
On October 1, 2013, Astex issued a supplemental Schedule 14D-9/A Solicitation/Recommendation Statement (the …
Shares of Sunesis Pharmaceuticals ... unblinding of the VALOR trial in 2013. The company went public in September 2005, offering its shares at $7 each. SNSS has thus far hit a 52-week low of $1.01 and a 52-week high of $3.16. The …